The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation.
BACKGROUND: Alloimmunity, autoimmunity, and nonspecific inflammation are known to be potential determinants for long-term islet survival and insulin independence. Sufficient islet mass is a key determinant. But islet engraftment and posttransplant survival may also depend on functional characteristi...
| Autors principals: | , , , , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2004
|
| _version_ | 1826266276189700096 |
|---|---|
| author | Eckhard, M Brandhorst, D Winter, D Jaeger, C Jahr, H Bretzel, R Brendel, MD |
| author_facet | Eckhard, M Brandhorst, D Winter, D Jaeger, C Jahr, H Bretzel, R Brendel, MD |
| author_sort | Eckhard, M |
| collection | OXFORD |
| description | BACKGROUND: Alloimmunity, autoimmunity, and nonspecific inflammation are known to be potential determinants for long-term islet survival and insulin independence. Sufficient islet mass is a key determinant. But islet engraftment and posttransplant survival may also depend on functional characteristics of the graft. This study investigated the significance of current product release criteria for the transplantation outcome. METHODS: Fourty five consecutive transplanted human islet preparations and their functional outcomes were analyzed. Islet mass was determined according to standard criteria: purity by light microscopy, viability by dye exclusion and Insulin secretory response to static glucose incubation. Islet graft function was monitored for > or = 1 year. Islet function was defined as full (FF), partial (PF), or nonfunction (NF) based on serum C-peptide levels and insulin independence. RESULTS: All islet grafts displayed primary function. Islet mass [IEQ/kg BW]: 7331.3 +/- 679.7 (FF), 5821.3 +/- 546.7 (PF), 6468.6 +/- 658.5 (NF), (FF vs PF p = .032) Purity [%] 86.9 +/- 3.1 (FF), 76.0 +/- 2.87 (PF), 88.2 +/- 2.3 (NF) (FF vs PF P =.045, PF vs NF, P = 0.01). (4) Viability [%]:89.2 +/- 2 (FF), 86.2 +/- 1.7 (PF), 87.3 +/- 1.8 (NF) (ns). Stimulation index (SI): 20 +/- 6.3 (FF), 80.2 +/- 28.2 (PF), 21.6 +/- 3.5 (NF) (ns) No correlation was observed between SI and any other parameter nor between SI and C-peptide levels. Islet mass significantly correlated with C-peptide levels at 6 and 12 months after transplantation for functioning grafts. CONCLUSIONS: Stringent product release criteria allow identification of islet preparations suitable for clinical transplantation. However, currently used parameters are not predictive of long-term graft function, indicating that further refined quality assessments including apoptosis and resistance to early inflammation, are required to assess the primary engrafted islet mass. |
| first_indexed | 2024-03-06T20:36:26Z |
| format | Journal article |
| id | oxford-uuid:32cb8abd-2b6b-421f-a29d-a49566b33b3a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:36:26Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:32cb8abd-2b6b-421f-a29d-a49566b33b3a2022-03-26T13:16:18ZThe role of current product release criteria for identification of human islet preparations suitable for clinical transplantation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:32cb8abd-2b6b-421f-a29d-a49566b33b3aEnglishSymplectic Elements at Oxford2004Eckhard, MBrandhorst, DWinter, DJaeger, CJahr, HBretzel, RBrendel, MDBACKGROUND: Alloimmunity, autoimmunity, and nonspecific inflammation are known to be potential determinants for long-term islet survival and insulin independence. Sufficient islet mass is a key determinant. But islet engraftment and posttransplant survival may also depend on functional characteristics of the graft. This study investigated the significance of current product release criteria for the transplantation outcome. METHODS: Fourty five consecutive transplanted human islet preparations and their functional outcomes were analyzed. Islet mass was determined according to standard criteria: purity by light microscopy, viability by dye exclusion and Insulin secretory response to static glucose incubation. Islet graft function was monitored for > or = 1 year. Islet function was defined as full (FF), partial (PF), or nonfunction (NF) based on serum C-peptide levels and insulin independence. RESULTS: All islet grafts displayed primary function. Islet mass [IEQ/kg BW]: 7331.3 +/- 679.7 (FF), 5821.3 +/- 546.7 (PF), 6468.6 +/- 658.5 (NF), (FF vs PF p = .032) Purity [%] 86.9 +/- 3.1 (FF), 76.0 +/- 2.87 (PF), 88.2 +/- 2.3 (NF) (FF vs PF P =.045, PF vs NF, P = 0.01). (4) Viability [%]:89.2 +/- 2 (FF), 86.2 +/- 1.7 (PF), 87.3 +/- 1.8 (NF) (ns). Stimulation index (SI): 20 +/- 6.3 (FF), 80.2 +/- 28.2 (PF), 21.6 +/- 3.5 (NF) (ns) No correlation was observed between SI and any other parameter nor between SI and C-peptide levels. Islet mass significantly correlated with C-peptide levels at 6 and 12 months after transplantation for functioning grafts. CONCLUSIONS: Stringent product release criteria allow identification of islet preparations suitable for clinical transplantation. However, currently used parameters are not predictive of long-term graft function, indicating that further refined quality assessments including apoptosis and resistance to early inflammation, are required to assess the primary engrafted islet mass. |
| spellingShingle | Eckhard, M Brandhorst, D Winter, D Jaeger, C Jahr, H Bretzel, R Brendel, MD The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title | The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title_full | The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title_fullStr | The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title_full_unstemmed | The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title_short | The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. |
| title_sort | role of current product release criteria for identification of human islet preparations suitable for clinical transplantation |
| work_keys_str_mv | AT eckhardm theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT brandhorstd theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT winterd theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT jaegerc theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT jahrh theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT bretzelr theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT brendelmd theroleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT eckhardm roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT brandhorstd roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT winterd roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT jaegerc roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT jahrh roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT bretzelr roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation AT brendelmd roleofcurrentproductreleasecriteriaforidentificationofhumanisletpreparationssuitableforclinicaltransplantation |